Resverlogix Corp RVXCF:OTCPK

*Data is delayed | Exchange | USD
Last | 05/03/24 EDT
0.04UNCH (UNCH)
Volume
7,000
52 week range
0.03 - 0.11
Loading...
  • Open0.04
  • Day High0.04
  • Day Low0.04
  • Prev Close0.04
  • 52 Week High0.11
  • 52 Week High Date05/05/23
  • 52 Week Low0.03
  • 52 Week Low Date03/28/24

Key Stats

  • Market Cap11.95M
  • Shares Out274.51M
  • 10 Day Average Volume4,420
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-24.53

KEY STATS

  • Open0.04
  • Day High0.04
  • Day Low0.04
  • Prev Close0.04
  • 52 Week High0.11
  • 52 Week High Date05/05/23
  • 52 Week Low0.03
  • 52 Week Low Date03/28/24
  • Market Cap11.95M
  • Shares Out274.51M
  • 10 Day Average Volume4,420
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-24.53

RATIOS/PROFITABILITY

  • EPS (TTM)-0.06
  • P/E (TTM)-0.64
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Resverlogix Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19...
Donald Mccaffrey
Chairman of the Board, President, Chief Executive Officer, Secretary
A. Brad Cann CPA
Chief Financial Officer
Address
300-4820 Richard Rd SW
Calgary, AB
T3E 6L1
Canada